NIH R01 · 2025
Neutrophil hyperexocytosis and hypochlorous acid exposure in early cystic fibrosis lung disease
PROJECT SUMMARY / ABSTRACT Current standard of care for cystic fibrosis (CF) does not include drugs unequivocally effective at curbing airway inflammation, in contrast to crucial gains made in correcting defects in the CF transmembrane conductance regulator (CFTR) via highly effective modulator therapy (HEMT) and an array of antimicrobial drugs. Effectively treating exuberant neutrophil-dominated inflammation in CF, particularly in the earliest stages of the disease, is a critical goal because doing so would increase patient lifespan and health span. This project is designed to test the hypothesis that neutrophil hyperexocytosis, which occurs in CF from a very young age, is a critical event…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.